Negative Press Doesn't Change UBS View on Horizon Pharma (HZNP)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Express Scripts (ESRX) Says Horizon Pharma (HZNP) Represented 40% of Linden Claims - Bloomberg, Citing Spokesperson
November 11, 2015 3:19 PM ESTExpress Scripts (NASDAQ: ESRX) says Horizon Pharma (NASDAQ: HZNP) represented 40 percent of Linden claims, according to Bloomberg, citing a company spokesperson.
... MoreHorizon Pharma (HZNP) Issues Commentary on Express Scripts' (ESRX) Business Practices
November 11, 2015 12:12 PM EST(NOTE - The following follows an earlier statement made by Horizon.)
Horizon Pharma plc (Nasdaq: HZNP) commented on Express Scripts' (Nasdaq: ESRX) business practices.
"Our philosophy of ensuring that patients get the medicine their doctors prescribe is threatening Express Scripts' profiteering and exposing what we believe is a lack of care for... More
Linden Disruption Expected to Have 'Minimal Impact' on Horizon Pharma (HZNP) - Mizuho
November 11, 2015 11:57 AM ESTMizuho Securities analyst Irina Koffler reiterated a Buy rating and $34 price target on Horizon Pharma (NASDAQ: HZNP), saying they expect minimal impact from Linden disruption.
Koffler commented, "We spoke with management and learned that Linden processes ~150-200 prescriptions for Duexis, Vimovo, Pennsaid, and... More
